Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
J Nutr Biochem ; 56: 193-204, 2018 06.
Artigo em Inglês | MEDLINE | ID: mdl-29587242

RESUMO

Anthocyanins (ANT) are polyphenolic flavonoids with antioxidant and neuroprotective properties. This study evaluated the effect of ANT treatment on cognitive performance and neurochemical parameters in an experimental model of sporadic dementia of Alzheimer's type (SDAT). Adult male rats were divided into four groups: control (1 ml/kg saline, once daily, by gavage), ANT (200 mg/kg, once daily, by gavage), streptozotocin (STZ, 3 mg/kg) and STZ plus ANT. STZ was administered via bilateral intracerebroventricular (ICV) injection (5 µl). ANT were administered after ICV injection for 25 days. Cognitive deficits (short-term memory and spatial memory), oxidative stress parameters, and acetylcholinesterase (AChE) and Na+-K+-ATPase activity in the cerebral cortex and hippocampus were evaluated. ANT treatment protected against the worsening of memory in STZ-induced SDAT. STZ promoted an increase in AChE and Na+-K+-ATPase total and isoform activity in both structures; ANT restored this change. STZ administration induced an increase in lipid peroxidation and decrease in the level of antioxidant enzymes, such as superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx), in the cerebral cortex; ANT significantly attenuated these effects. In the hippocampus, an increase in reactive oxygen species (ROS), nitrite and lipid peroxidation levels, and SOD activity and a decrease in CAT and GPx activity were seen after STZ injection. ANT protected against the changes in ROS and antioxidant enzyme levels. In conclusion, the present study showed that treatment with ANT attenuated memory deficits, protected against oxidative damage in the brain, and restored AChE and ion pump activity in an STZ-induced SDAT in rats.


Assuntos
Doença de Alzheimer/tratamento farmacológico , Antocianinas/farmacologia , Bombas de Íon/metabolismo , Transtornos da Memória/tratamento farmacológico , Estresse Oxidativo , Acetilcolinesterase/metabolismo , Doença de Alzheimer/induzido quimicamente , Animais , Antioxidantes/uso terapêutico , Encéfalo/metabolismo , Catalase/metabolismo , Córtex Cerebral/metabolismo , Cognição , Modelos Animais de Doenças , Glutationa Peroxidase/metabolismo , Hipocampo/metabolismo , Infusões Intraventriculares , Peroxidação de Lipídeos , Masculino , Aprendizagem em Labirinto , Memória/efeitos dos fármacos , Transtornos da Memória/induzido quimicamente , Fármacos Neuroprotetores/uso terapêutico , Ratos , Ratos Wistar , Estreptozocina/efeitos adversos , Compostos de Sulfidrila , Superóxido Dismutase/metabolismo
2.
Pharmacol Biochem Behav ; 102(1): 21-9, 2012 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-22484161

RESUMO

In this study, the antioxidant and antidepressant-like effects of α-(phenylselanyl) acetophenone (PSAP), an organoselenium compound, were investigated. To assess the in vitro antioxidant properties, PSAP was evaluated in four test systems (DPPH, ABTS, FRAP and inhibition of lipid peroxidation). PSAP (100-500 µM) showed potent antioxidant activity and protected against lipid peroxidation. Additionally, we investigated whether PSAP, when administered in mice (100, 200 and 400mg/kg, per oral, p.o.), could cause acute toxicity. Our results demonstrated that PSAP did not cause the death of any animal, significantly reduce body weight or cause any oxidative tissue stress following treatment. This study also evaluated the effect of PSAP (0.1-10 mg/kg, p.o) on mice in a forced swim test (FST) and tail suspension test (TST), assays that are predictive of depressant activity and motor activity in the open-field. PSAP (5-10 mg/kg) significantly reduced immobility time in the FST and TST without affecting motor activity. In addition, the antidepressant-like effect caused by PSAP (5m/kg, p.o) in mice during the TST was dependent on an interaction with the serotonergic system (5-HT(1A) receptors), but not with the noradrenergic, dopaminergic or adenosinergic system. Together, these results suggest that PSAP possesses antioxidant and antidepressant-like properties and may be of interest as a therapeutic agent for the treatment of depressive disorders.


Assuntos
Acetofenonas/química , Acetofenonas/uso terapêutico , Antidepressivos/química , Antidepressivos/uso terapêutico , Antioxidantes/química , Antioxidantes/farmacologia , Compostos Organosselênicos/química , Compostos Organosselênicos/uso terapêutico , Acetofenonas/administração & dosagem , Animais , Antidepressivos/administração & dosagem , Antioxidantes/uso terapêutico , Depressão/tratamento farmacológico , Depressão/metabolismo , Peroxidação de Lipídeos/efeitos dos fármacos , Peroxidação de Lipídeos/fisiologia , Masculino , Camundongos , Compostos Organosselênicos/administração & dosagem , Distribuição Aleatória , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA